AttendMe Owl Logo
AttendMe
Evidence Evolution
Trauma SurgeryTrauma Surgery

How This Evidence Evolved

Massive Transfusion Protocols

From Crystalloid-First to Hemostatic Resuscitation

31.2

Timeline

Borgman 2007
2007
ABC score
2009
PROPPR
2015
T-STORHM
2019
CRYOSTAT-2
2023
European guideline on management of major bleeding and coagulopathy following trauma, sixth edition
2023
European guideline on management of major bleeding and coagulopathy following trauma, sixth edition
2023
ITACTIC
2024
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

Severely injured patients often present with coagulopathy and need massive transfusion, and some proposed early, aggressive correction with a 1:1 ratio of plasma to red blood cells (RBCs). In 2007, Borgman and colleagues reviewed 246 patients who received at least 10 RBC units in 24 hours at a US Army combat support hospital. Overall mortality was 65%, 34% and 19% with low (median 1:8), medium (1:2.5) and high (1:1.4) plasma:RBC ratios (p<0.001), and a high ratio was independently associated with survival (OR 8.6, 95% CI 2.1-35.2), mainly through fewer hemorrhage deaths. The authors advised a 1:1 plasma:RBC ratio in massive transfusion protocols for hypocoagulable patients with traumatic injuries.
Proof

Landmark RCTs and pivotal trials that established the evidence base

PROPPR randomized 680 severely injured patients predicted to require massive transfusion to plasma:platelets:RBC ratios of 1:1:1 or 1:1:2. Mortality did not differ significantly at 24 hours (12.7% versus 17.0%, P=.12) or 30 days (22.4% versus 26.1%, P=.26). More patients achieved hemostasis with 1:1:1 (86% versus 78%, P=.006), and 24-hour exsanguination deaths were fewer (9.2% versus 14.6%, P=.03). The trial found no differences in the 23 prespecified complications despite greater plasma and platelet use; it did not establish faster hemostasis or worldwide adoption.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Two major extensions have refined massive transfusion practice. First, whole blood has re-emerged as a resuscitation product: low-titer group O whole blood provides balanced hemostatic resuscitation in a single product, simplifying logistics. The randomized T-STORHM trial was designed in 2019 to compare it with component therapy for in-hospital management of trauma patients with massive hemorrhage. Second, viscoelastic hemostatic assays (TEG and ROTEM) have enabled goal-directed transfusion, allowing clinicians to identify specific coagulation deficits and target therapy rather than empirically transfusing fixed ratios. The ITACTIC trial compared viscoelastic-guided with conventional test-guided algorithms and found no difference in 28-day mortality; in a secondary analysis of 133 patients, only 54% received goal-directed treatment and only 20% corrected their coagulopathy.
Guidelines

Integration into clinical practice guidelines and recommendations

The European bleeding guideline, sixth edition, recommends two initial strategies for expected massive hemorrhage: fibrinogen concentrate or cryoprecipitate plus RBCs, or FFP with an FFP:RBC ratio ≥1:2 as needed (Grade 1C). Ongoing treatment should be goal-directed using laboratory tests and/or viscoelastic monitoring. Early activation before laboratory confirmation remains a clinical consideration; fixed-ratio survival data are equivocal.
European guideline on management of major bleeding and coagulopathy following trauma, sixth edition

Expected massive hemorrhage: FFP:RBC ≥1:2 as needed or fibrinogen/cryo plus RBCs (Grade 1C); guide ongoing therapy by laboratory tests/VEM.

Now

Current standard of care and ongoing research directions

European guidance combines an initial expected-massive-hemorrhage strategy with goal-directed refinement. T-STORHM was designed to compare low-titer group O whole blood with components in hospital trauma care; its design paper reports no results. CRYOSTAT-2 tested early empirical high-dose cryoprecipitate added to standard care: 28-day mortality was 25.3% versus 26.1% (OR 0.96, 95% CI 0.75–1.23), without benefit. This differs from deficit-guided fibrinogen replacement. Questions include prehospital delivery, dried plasma, artificial oxygen carriers and whether machine learning can predict transfusion need.

Landmark Trials in This Story

Borgman 20072007Landmark

The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital

Mortality by plasma:RBC ratio

The Journal of traumaRetrospective cohortN=246
PROPPR2015Landmark

Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial

24-hour and 30-day all-cause mortality

JAMARCTN=680
ITACTIC2024

Correction of Trauma-induced Coagulopathy by Goal-directed Therapy: A Secondary Analysis of the ITACTIC Trial

Coagulopathy correction by RBC 12

AnesthesiologySecondary subgroup analysis of ITACTIC patients coenrolled in a prospective observational studyN=133
T-STORHM2019

Rational and design of the T-STORHM Study: A prospective randomized trial comparing fresh whole blood to blood components for acutely bleeding trauma patients.

No results reported (design paper): low-titer group O whole blood vs blood components for in-hospital management of trauma with massive hemorrhage

Transfus Clin BiolProspective randomized multicentre trial (design paper; 6 civilian and military trauma centres planned)
ABC score2009

Early prediction of massive transfusion in trauma: simple as ABC (assessment of blood consumption)?

ABC score ≥2 predicted massive transfusion: sensitivity 75%, specificity 86%; 596 analyzed adults.

The Journal of traumaRetrospective cohort studyN=596
CRYOSTAT-22023

Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial.

All-cause mortality at 28 days: cryoprecipitate 25.3% vs standard care 26.1% (OR 0.96, 95% CI 0.75–1.23; P=.74); thrombotic events 12.7% vs 12.9%. Primary analysis included 1531 patients.

JAMAInternational multicenter randomized open-label parallel-group trial of early empirical high-dose cryoprecipitate plus standard major-hemorrhage care versus standard careN=1,604

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

What is the evidence for 1:1:1 versus 1:1:2 blood product ratios?+
The PROPPR trial (2015) randomized 680 severely injured patients predicted to need massive transfusion to 1:1:1 versus 1:1:2 (plasma:platelets:RBCs). Mortality did not differ at 24 hours (12.7% vs 17.0%, P=.12) or 30 days (22.4% vs 26.1%, P=.26), but more 1:1:1 patients achieved hemostasis (86% vs 78%, P=.006) and fewer died of exsanguination by 24 hours (9.2% vs 14.6%, P=.03). None of 23 prespecified complications, including ARDS and transfusion-related complications, differed.
When should a massive transfusion protocol be activated?+
In a retrospective study of 596 adults, ABC ≥2 predicted massive transfusion (75% sensitivity, 86% specificity); inputs were penetrating mechanism, positive FAST, SBP ≤90 mmHg and HR ≥120/min. The European trauma guideline recommends combining physiology, anatomical injury, mechanism and response to resuscitation, rather than relying on a single predictor. Activate promptly when clinically indicated; confirm local thresholds.
What is the role of whole blood in trauma resuscitation?+
Low-titer group O whole blood provides balanced resuscitation (RBCs, plasma, platelets, and clotting factors) in a single product, which may simplify component-delivery logistics. The randomized T-STORHM trial was designed to compare low-titer group O whole blood with component therapy in the in-hospital management of trauma patients with massive hemorrhage.
How do viscoelastic assays (TEG/ROTEM) change transfusion management?+
Use early, repeated laboratory and/or viscoelastic monitoring to guide coagulation treatment. The European trauma guideline recommends goal-directed resuscitation (Grade 1B), FFP for demonstrated factor deficiency, and fibrinogen concentrate or cryoprecipitate for major bleeding with functional fibrinogen deficit or Clauss fibrinogen ≤1.5 g/L. It suggests platelets to maintain counts above 50 × 10⁹/L in ongoing bleeding, or 100 × 10⁹/L with TBI. TXA administration should not await viscoelastic results. Assay choice alone does not guarantee a mortality benefit.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026